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Background: The effectiveness of the psychotherapeutic treatment of posttraumatic stress 
disorder is evidence-based and generally considered proven. However, the effectiveness 
of multimodal, group-based day clinic treatment programs has rarely been investigated. 
Moreover, there is no consensus in the literature concerning the question whether 
psychotherapeutic approaches for trauma-related disorders are also applicable for patients 
with complex PTSD (cPTSD). The aim of the study was to evaluate our multimodal group-
based treatment program regarding a change of psychiatric burden, a change of protective 
factors, and possible differences in therapy outcome for patients with or without cPTSD.
Methods: The group-based treatment for patients with trauma-related disorders was 
examined in 66 patients who filled out the following questionnaires in the first and in 
the last week of treatment: Essen Trauma Inventory (ETI), Screening for complex 
PTSD (SkPTBS), Patient Health Questionnaire—somatization module (PHQ-15), Beck 
Depression Inventory—Revised (BDI-II), Posttraumatic Growth Inventory (PTGI), and 
Questionnaire on social support (F-SozU).
Results: The treatment was shown to significantly reduce depressive symptoms (p < 
0.001, d = -0.536) and increase posttraumatic growth (New Possibilities: p = 0.004, d = 
0.405; Personal Strength: p = 0.005, d = 0.414). For patients with cPTSD, depressive 
(p = 0.010, d = -0.63) as well as cPTSD symptoms (p = 0.020, d = -0.796) were significantly 
reduced; perceived social support was increased after day clinic treatment (p = 0.003, d = 
0.61). Contrary to our expectations, somatoform symptoms were increased after therapy.
Conclusions: The present work expands previous research by demonstrating that 
multimodal group-based, day clinic treatment is effective in the treatment of trauma-
related disorders, also in their complex form.
Keywords: trauma, posttraumatic stress disorder, complex PTSD, therapy outcome, day clinic treatment, 
posttraumatic growth, social support, depression
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iNTRODUCTiON
The prevalence of traumatic experiences throughout lifetime 
is high: in the US national comorbidity survey, 60.7% of men 
and 51.2% of women reported having experienced at least one 
traumatic event in their lifetime (1). Not all of these persons 
develop a psychiatric disease in the aftermath of trauma. 
However, 10% to 50% of survivors may develop a posttraumatic 
stress disorder (PTSD), depending on the type of the traumatic 
event (e.g., after automobile accidents or after rape, respectively) 
(2), or react with depressive, anxiety, or somatoform symptoms 
(2) or complex profiles. Other studies reported lower PTSD rates 
after various traumatic experiences (e.g., 19% after rape) (3). 
In a nationwide representative German sample, the 1-month 
prevalence rate for PTSD in the whole population (irrespective of 
having been confronted with a traumatic event) was 1.5% and for 
complex PTSD (cPTSD) 0.5% (4). For these persons, specialized 
treatment of trauma-related disorders is of utmost relevance.
The effectiveness of many psychotherapeutic treatments 
of PTSD and other trauma-related disorders is considered 
proven (5, 6, 7). Additionally, group-based programs have 
been examined and were shown to reduce trauma-related 
symptomatology (8, 9). For example, Sloan et al. (10) conducted 
a meta-analysis for group-based treatment programs and showed 
a small but significant effect. Treatment approaches combining 
individual and group therapy have rarely been examined, despite 
promising effects that were yielded by addressing more than 
one treatment target area, as Sloan et al. (11) stated. The authors 
concluded that more work is needed to examine the combination 
of group and individual treatment. In a meta-analysis with 
military samples, group-only therapy formats were shown to be 
less effective than individual-only or combinatory formats (12). 
Our study investigates a multimodal therapy program combining 
individual and group-based psychotherapy in a day clinic setting.
Previous studies supported evidence for the effectiveness of 
inpatient treatment programs for trauma-related disorders (13, 
14). In Germany, the discipline of psychosomatic medicine and 
psychotherapy provides inpatient multimodal treatment, which 
is reimbursed by health insurance and offers a dense program of 
different therapy modules. Despite the wide use of such programs 
in German psychosomatics departments and clinics, only very 
few studies investigated their therapy outcomes. Lampe et al. 
(15, 16) showed a significant reduction of depressive symptoms 
as well as an increase in self-calming ability in inpatients with a 
history of sexual abuse in childhood treated over 6 weeks. No 
differences to the wait-list control group were found for PTSD, 
anxiety, and somatization symptoms. In a follow-up 2 years later, 
a significant reduction of overall symptom severity, PTSD, and 
depressive symptoms as well as an increase in self-calming ability 
were reported (16). Other examinations of inpatient treatment 
programs found significant improvements in dissociation, stress 
reaction and defense mechanisms (17), reductions of PTSD 
symptoms and improvements concerning feelings of self-esteem, 
freedom, and security (18) and improvements in PTSD, depressive 
and dissociative symptoms, as well as in interpersonal problems 
and general psychopathology (19). These improvements were 
found to be stable over a 1-year follow-up period. Lower effects 
were found for patients with complex dissociative disorders (19). 
In a following investigation, the authors showed dissociative 
symptoms and interpersonal problems previous to admission as 
well as their interaction to predict poorer therapy outcome (20).
To our knowledge, this is the first study to examine a 
multimodal, group-based day clinic treatment for trauma-
related disorders. Day clinic programs have several advantages 
over inpatient treatment: Patients are still connected to their 
everyday life, which strengthens transfer of learned techniques 
and facilitates working on important problems or difficulties 
that would not be present during inpatient treatment. Patients 
can stay in their well-known environment and are able to spend 
evenings and nights in their own home, which may reflect an 
important safety anchor. Apart from that, day clinic programs 
are more cost-effective than inpatient treatments. Given these 
advantages, it is important to investigate the effectiveness of such 
treatment programs.
A growing number of studies pay attention to the question 
if therapy outcome differentiates for patients with classic versus 
complex PTSD and if treatment programs therefore need 
to account for this difference. cPTSD describes a symptom 
pattern that goes beyond classic PTSD symptoms and includes 
difficulties in emotion regulation (e.g., increased emotional 
reactivity, self-harming behavior), alterations in self-concept, 
e.g., disturbed feeling of identity, belief to live a shattered life 
or to be worthless, permanent feelings of guilt and shame, and 
relationship problems, e.g., inability to trust others or to be in 
a stable relationship (21, 22, 23). cPTSD is caused by severe 
interpersonal trauma that often lasted for a long period, such 
as sexual abuse in childhood or other forms of violence (21, 
22, 24). To date, the two classification systems of ICD-11 and 
DSM-5 are not congruent in their definitions of PTSD or in 
their inclusion of the concept of cPTSD. cPTSD is not an official 
concept according to DSM-IV and DSM-5, but will be included 
in ICD-11. European countries differ in which classification 
system they use. Until now, the concept of cPTSD has been coded 
under different names in the diagnostic systems [e.g., Disorders 
of Extreme Stress Not Otherwise Specified (DESNOS)] and there 
is an ongoing debate about the significance and diagnostic entity 
of cPTSD [for an overview see (25)]. Although the symptom 
pattern of cPTSD has been examined for many years, there is still 
a controversy about presence, clinical significance, and treatment 
implications (26). It is unclear whether cPTSD patients are able 
to tolerate and benefit from first-line PTSD treatments; those 
often do not target all relevant psychopathology of cPTSD, e.g., 
affect regulation or interpersonal problems (24). Many studies 
excluded patients with complex clinical profiles (e.g., sexual 
abuse in childhood, personality disorders), so that only a limited 
amount of literature exists concerning the question whether 
cPTSD is a negative prognostic factor for therapy outcome (27).
A meta-analysis concerning treatments for child abuse-related 
cPTSD found a mean effect size of 1.7 (1.3 in the intention-to-
treat-analysis) (24). cPTSD patients showed less treatment gain 
than non-complex PTSD patients as well as lower recovery 
rates and a lower improvement rate. Generally, only a minority 
of patients reached criteria for significant improvement after 
therapy. Another recent meta-analysis (28) indicates that group 
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treatments for adults with symptoms associated with cPTSD are 
effective in reducing several psychopathological factors (e.g., 
PTSD symptoms, depression, and psychological distress). In 
an examination of an inpatient multimodal treatment program 
for patients with cPTSD, Kratzer et al. (29) found a reduction 
of PTSD, depressive, somatoform, and anxiety symptoms as well 
as an increase in well-being, self-efficacy, and mindfulness. They 
concluded that trauma-focused therapy is also applicable for 
patients with cPTSD. Cloitre et al. (26) recommended a phase-
based approach for patients with cPTSD in their expert consensus 
statement for the International Society for Traumatic Stress 
Studies. A review of the existing literature showed effects ranging 
from g = -0.90 for cognitive behavioral therapy (CBT) to g = -1.26 
for eye movement desensitization and reprocessing (EMDR) 
therapy with low number-needed-to-treat (NNT) indices (30). 
A moderator analysis showed childhood onset trauma to be 
associated with poorer outcome. The authors recommended 
exploring whether there are differences in outcome between 
patients fulfilling criteria for cPTSD and those who do not meet 
the diagnosis and to investigate the effectiveness of interventions 
using a dedicated measure for cPTSD, which is an aim of the 
present study.
Protective factors were also investigated in the present study. 
As Sloan et al. (11) stated, outcome measures other than PTSD, 
for example social functioning, should be investigated in clinical 
studies. Treatments for PTSD aim to enhance psychosocial 
functions observed in resilient individuals such as social support, 
emotion regulation, positive affect, meaning making, and post-
traumatic growth. Whether this goal is actually achieved has 
rarely been investigated; only a few studies included resilience 
factors as outcome variables (31).
An advantage of group-based treatment is the enhancement 
of social support and contact to other patients with a comparable 
history (e.g., cohesion, universality) (11, 32), but perceived social 
support has rarely been examined as outcome variable. Perceived 
social support by significant others was shown to moderate 
treatment outcome, indicating that higher perceived social 
support at the beginning is associated with greater reduction 
of PTSD symptoms in the treatment group (33). The authors 
questioned if perceived social support can be increased by 
therapy and stated that more research is needed in this field. In 
another examination, a positive association was found between 
social support during therapy and reduction of PTSD symptoms, 
as well as an increase in social support (34).
Another important protective factor is posttraumatic growth 
(PTG). The term describes “positive psychological change 
experienced as a result of the struggle with highly challenging 
life circumstances” (35) and consists of five factors: personal 
strength, new possibilities, relating to others, appreciation of 
life, and spiritual change (36). PTG and negative consequences 
of trauma such as PTSD are separate dimensions whose 
association is not definitely clear: Some studies found a positive 
(37, 38), others a negative association (39, 40), a third group 
detected no correlation at all (41, 42). Some authors assumed a 
curvilinear relationship in form of an inverted “U,” a Janus Faced 
improvement, so that minimal or extreme PTSD symptoms 
relate to a low extent of PTG (40). Previous research was able to 
show an increase of PTG or different subscales after treatment 
(37, 39, 40).
The aim of the present study was to evaluate our multimodal 
group-based treatment program regarding a change of psychiatric 
burden, a change of protective factors, and possible differences in 
therapy outcome for patients with or without cPTSD.
We hypothesized a reduction of psychiatric burden measured 
by PTSD, cPTSD, depressive and somatoform symptoms, as well 
as an increase in perceived social support and PTG. Further, we 
explored the following question: Are there differences concerning 
therapy outcomes between patients with cPTSD versus patients 
with non-complex trauma-related disorders?
MaTERialS aND METhODS
Treatment Description
Since 2014, the day clinic of the Department of Psychosomatic 
Medicine and Psychotherapy at the University Hospital Erlangen 
offers a specialized treatment of trauma-related disorders. 
Trauma-related disorders include PTSD in its classic or complex 
form as well as anxiety, affective, somatoform, or personality 
disorders that relate to traumatic experiences in the past. 
Exclusion criteria are acute psychosis, acute suicidality, present 
substance abuse or dependence, clear underweight (BMI < 17 kg/
m2), unstable social conditions such as homelessness, a journey 
to the day clinic of more than 1 h, contact to the offender, or not 
being able to participate in groups (e.g., extreme dissociation).
Trauma-focused therapy is carried out in a closed group 
format, so that seven patients enter and complete treatment 
together. Program modules are the following: psychotherapy 
in individual (1 × 50 min) and group (2 × 100 min) format, 
trauma-specific psychoeducation (1 × 100 min), skills training 
(2 × 60 min), mindfulness and relaxation methods (2 × 50 min), 
art therapy (1 ×  120 min), concentrative movement therapy (CMT, 
1 × 120 min), and pharmacological therapy if needed. Treatment 
quality is ensured by weekly team meetings and internal as well 
as external supervision. Psychotherapeutic treatment includes 
cognitive behavioral as well as psychodynamic techniques. 
Stabilizing and confrontational methods are used, the amount of 
each is chosen by the therapists on the basis of therapy goals and the 
patient`s status in the therapeutic process. Stabilization includes 
not only psychoeducation and training in affect regulation but also 
employment of problem- and solution-oriented coping techniques, 
distancing methods, and cognitive restructuring of trauma-related 
thoughts. Symptoms that lower psychosocial functioning (e.g., 
interactional problems) are treated.
Design and Procedure
Data were assessed in a longitudinal, naturalistic design. Every 
patient who started therapy in the group for patients with 
trauma-related disorders was asked to participate in our study. 
Written informed consent was obtained from every participant. 
Seventy-three patients were asked to participate; 66 (90.4%) 
gave their written consent. The study was approved by the ethics 
committee of the Medical Faculty of the Friedrich-Alexander 
University Erlangen-Nürnberg (FAU) (153_18B). After being 
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informed about study course, goals, and potential risks (e.g., 
being reminded of traumatic experiences while filling out 
questionnaires), participants completed the questionnaires 
described in section Instruments (T1 in week 1). These were also 
used for therapy planning and diagnosing by the psychotherapists 
that carried out therapy. In week 8, participants completed the 
same questionnaires again (T2).
instruments
The Essen Trauma Inventory (ETI) (43) contains a list of potentially 
traumatic experiences, questions concerning objective and 
subjective threat to life (criteria A1 and A2), and questions about 
symptoms on the subscales intrusion, hyperarousal, avoidance, 
and dissociation. Symptoms are rated on a 4-point Likert-type 
scale ranging from “0 = never” to “3 = very often”.  Clinically 
relevant PTSD is indicated by existence of a traumatic experience, 
a fulfilled A1 and A2 criteria as well as a symptom sum score ≥ 27. 
As the ETI is based on DSM-IV, the cut-off only covers the sum 
of the three subscales intrusion, hyperarousal, and avoidance; the 
items concerning the dissociation subscale are not involved in 
the cut-off score. The ETI was proven to be a reliable and valid 
questionnaire (43). In our study, Cronbach's alpha was α = 0.943 
for T1 and α = 0.953 for T2.
The Screening for complex PTSD (in German, SkPTBS) (44) 
is a questionnaire that assesses potentially traumatic experiences, 
risk and protective factors like age at onset, frequency and 
duration, type of causation (e.g., family member, accident) and 
complex PTSD symptoms. These include difficulties in affect 
and impulse control (e.g., self-calming ability, anger control), 
interactional problems (e.g., ability to trust another person), 
negative self-image (e.g., feelings of guilt, belief to live a shattered 
life), and dissociative symptoms. Symptoms are rated on a 
7-point Likert scale ranging from “0 = does not apply at all” to 
“6 = totally fits”. A high total value therefore reflects a high amount 
of complex PTSD symptomatology. Comparative values and a 
division into very high, high, and low risk for complex PTSD are 
also given. Dorr et al. (44) showed the scale to be reliable, one-
dimensional, and valid. Cronbach's alpha was α = 0.891 for T1 
and α = 0.904 for T2.
The Patient Health Questionnaire: somatization module 
(PHQ-15) (45) consists of 13 items measuring somatic symptoms 
with the response options “not bothered at all” (0), “bothered 
a little” (1), or “bothered a lot” (2). Two additional items from 
the depression module are included in the sum score; these 
assess sleeping disorders and tiredness. The possible range of 
the resulting sum score is 0 to 30 points. Sum scores of 5, 10, 
and 15 represent cut-offs for mild, moderate, and severe levels 
of somatization. For the PHQ-15, good psychometric properties 
have been demonstrated (46). In our study, Cronbach's alpha was 
α = 0.772 for T1 and α = 0.826 for T2.
The Beck Depression Inventory-Revised [BDI-II (47), 
German version (48)] is a 21-item questionnaire considering a 
variety of depressive symptoms such as sadness, feelings of guilt, 
insufficiency or worthlessness, and reduced interest in others 
as experienced within the last 2 weeks. Responses are rated 
on a 4-point scale ranging from 0 to 3 anchored with example 
sentences. Sum scores can be assigned to severity of depression 
symptoms using the following scheme: 0–8 no depression, 
9–13 minimal, 14–19 mild, 20–28 moderate, and 29–63 severe 
depression. The authors demonstrated good reliability and 
validity for the BDI-II. Internal consistency in our study was α = 
0.904 for T1 and α = 0.927 for T2.
The Posttraumatic Growth Inventory [PTGI (49), German 
version (50)] is a 21-item questionnaire that asks about positive 
change in the aftermath of a traumatic experience and consists 
of five subscales: New Possibilities (e.g., “I developed new 
interests.”), Relating to Others (e.g., “Having compassion for 
others.”), Personal Strength (e.g., “I discovered that I’m stronger 
than I thought I was.”), Appreciation of Life (e.g., “I changed my 
priorities about what is important in life.”), and Spiritual Change 
(e.g., “I have a stronger religious faith.”). Responses are rated on 
a 6-point Likert-type scale ranging from “0 = not at all” to “5 = 
very much”. Scores are calculated by adding the respective items 
with higher scores indicating higher PTG. The authors were 
able to show good psychometric properties for the PTGI and 
the corresponding German version. We adapted the instruction 
according to our study population: In an introductory sentence, 
we explained why patients are asked about positive changes after 
traumatic experiences to prevent feelings of not being understood 
or taken seriously in their sorrow. Patients were asked to name 
the most distressing traumatic event and their age at time of the 
experience. Internal consistency was α = 0.920 for T1 and α = 
0.917 for T2.
The Questionnaire on social support (in German: Fragebogen 
zur sozialen Unterstützung, F-SozU) (51) is a self-rating 
instrument measuring perceived social support. We used the 
short version K-14 consisting of 14 items such as “There are 
people who share joy and sorrow with me” or “I have no problems 
finding someone who looks after my flat when I’m not there”. 
Answers to these statements are rated on a 5-point scale ranging 
from “0 = does not apply at all” to “4 = totally fits”. The authors 
recommend only calculating a total score due to small item 
numbers when calculating subscales. A factor analysis confirmed 
that all items load on one factor. The F-SozU K-14 demonstrated 
good reliability and validity. Cronbach’s alpha in our study was 
α = 0.952 for T1 and α = 0.956 for T2.
Statistical analysis
Statistical analysis was performed using SPSS 25 (IBM Statistics, 
Chicago, IL, USA). After analyzing missing values with Little’s 
MCAR test (52), values that were missing completely at random 
were replaced using expectation maximization (EM) method 
(53). Dropout was very low (N = 2, 3.0%), so that missing T2 
scores could be replaced using the “last value carried forward” 
method (11). Hence, results are based on an intention to treat 
analysis (54, 55). An analysis of outlier scores indicated that the 
data contained only few outliers. These were left in the sample 
because of the plausibility of the scores and the natural variability 
in the sample.
Division of patients with complex trauma-related disorder 
versus non-complex disorders was made using the SkPTBS scores 
(see instruments). As n = 49 patients (75.4%) were classified as 
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being on a high risk of having complex PTSD, we decided to use 
the more strict cut-off of being on a very high risk for complex 
PTSD (e.g., reaching a score of 28,19 or higher).
To profile the sociodemographic characteristics of the total 
sample and the subsamples, the following descriptive statistics 
were computed: means, standard deviations, ranges, and 
frequencies.
Evaluation of our treatment program is provided for the total 
sample as well as for the sub-groups of patients with or without 
complex PTSD, respectively. For the total sample, comparisons 
were analyzed using t-tests. For the sub-group analyses, we first 
verified if data was normally distributed because of low sample 
sizes. If values were not normally distributed, we conducted non-
parametric Wilcoxon tests instead of t-tests. Significance level in 
all analyses was p ≤ 0.05. To measure the effect size, we computed 
Cohen's d.
RESUlTS
Sample Characteristics
Our study included N = 66 patients: 55 females (83.3%) and 11 
males (16.7%). Males were significantly older (M = 50.00, SD = 
9.26) than females (M = 38.07, SD = 13.18; t = -3.60, df = 19.15, 
p = 0.002). Treatment diagnoses given on the basis of clinical 
impression and questionnaires are depicted in Table 1. Of the 
53 patients diagnosed with a PTSD, 22 were diagnosed with 
the appendix “complex.” The diagnosis of emotionally unstable 
personality disorder was given in five of the seven patients with 
the main diagnosis personality disorder. In a further patient, this 
was a comorbid diagnosis. Comorbidity with other psychiatric 
disorders as well as the number of diagnoses were high (see Table 
1). Information on pharmacological treatment was gathered 
from patient records. Forty-two patients (63.6%) were treated 
with antidepressants, 18 (27.3%) with neuroleptic medication, 
5 (7.6%) received benzodiazepines, 24 (36.4%) took analgesics, 
and 48 (72.2%) received various pharmacological treatment for 
chronical conditions.
Sociodemographic variables and data concerning pretreatment 
are shown in Table 2. No significant differences between the 
subgroups were found, except for the frequency of pretreatment 
inpatient admissions: There was a significant association between 
being on a very high risk for cPTSD and reporting inpatient 
treatment in the past [χ² (1) = 4.196, Fisher's exact test p = 0.048]. 
cPTSD patients more often reported inpatient treatment before 
being admitted to our group treatment.
Traumatic Events
Sixty-five patients (98.5%) reported having experienced and/or 
witnessed traumatic events (TE). The one person who reported 
not having experienced any TE was diagnosed with a complex 
PTSD, so that self-report on the ETI and reported biographical 
information in psychotherapy did not match and the person was 
left in the sample for the following analyses. Table 3 shows the 
distribution of the most frequent TE for the total sample and 
the different subgroups as well as the amount of patients having 
experienced persistent TE and sexual violence in their infancy.
Treatment Evaluation
As shown in Table 4, depressive symptoms were significantly 
reduced at T2 (t = 3.977, df = 64, p < 0.001) with an effect size 
of Cohen’s d = -0.536, indicating a medium effect. Also, two 
dimensions of the PTGI significantly increased (see Table  5): 
New Possibilities (t = -2.993, df = 49, p = 0.004, Cohen’s d = 
0.405) and Personal Strength (t = -2.919, df = 50, p = 0.005, 
Cohen’s d = 0.414). The PTGI total score was found to show a 
trend to be increased (t = -1.993, df = 49, p = 0.052, Cohen’s d = 
0.277), as too did perceived social support (t = -1.784, df = 65, p = 
0.079, Cohen’s d = 0.216). Contrary to our hypothesis, we found 
a significant increase in the somatization scores (see Table 4). No 
other indices showed a significant change over time.
Patients with and without cPTSD differed significantly on T1 
und T2 symptom scores: cPTSD patients had significantly higher 
scores on almost all symptom scores (e.g., ETI, BDI-II). cPTSD 
patients also had significantly lower scores at T1 for perceived 
social support. Data are shown in corresponding tables in the 
Supplementary Material.
We then conducted a sub-group analysis and evaluated the 
treatment program for patients with complex PTSD versus those 
with non-complex trauma-related disorders, respectively. For 
results, see Tables 6, 7, 8, and 9.
For patients with non-complex trauma-related disorders, we 
found a significant reduction of depressive symptoms (t = 2.989, 
df = 36, p = 0.005, d = -0.554, see Table 6) as well as a significant 
increase on two PTGI scales (see Table 7): New Possibilities 
(t = -3.117, df = 29, p = 0.004, d = 0.547) and Personal Strength 
TaBlE 1 | Distribution of main diagnoses, comorbidity, and number of 
diagnoses.
N %
Main Diagnosis
Posttraumatic stress disorder 46 69.70
Other reactions to severe stress 7 10.61
Personality disorders 7 10.61
Depressive disorders 5 7.58
Obsessive compulsive disorder 1 1.52
Comorbid Diagnoses
Depressive disorders 60 90.91
Somatoform disorders 15 22.73
Anxiety disorders 11 16.67
Posttraumatic stress disorder 7 10.61
Obsessive compulsive disorder 5 7.58
Personality disorders 4 6.06
Eating disorders 4 6.06
Substance abuse 3 4.55
Dissociative disorders 2 3.03
Impulse control disorders 1 1.52
Hyperkinetic disorders 1 1.52
Number of diagnoses1
1 diagnosis 1 1.52
2 diagnoses 31 46.97
3 diagnoses 19 28.79
4 diagnoses 11 16.67
5 diagnoses 4 6.06
1Without consideration of possible somatic diagnoses.
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(t = -2.501, df = 30, p = 0.018, d = 0.443). The PTGI total score 
showed an increase (t = -1.857, df = 29, p = 0.074, d = 0.332). On 
the other hand, somatoform symptoms tended to be increased 
(p = 0.078, d = 0.314), but this increase was not statistically 
significant. Also complex PTSD symptoms showed a significant 
increase (p = 0.022, d = 1.169).
For patients with complex PTSD, results showed quite a 
different pattern: Depressive symptoms (t = 2.759, df = 26, 
p = 0.010, d = -0.63) as well as complex PTSD symptoms (p = 
0.020, d = -0.796) were significantly reduced (see Table 8). Also, 
perceived social support showed a highly significant increase 
(t = -3.243, df = 27, p = 0.003, d = 0.61, see Table 9). All three 
TaBlE 2 | Sociodemographic and pretreatment variables.
Total sample 
(N = 66)
Females (N=55) Males (N = 11) Complex PTSD 
(N=28)
Non-Complex 
(N = 37)
M (SD) Range M (SD) Range M (SD) Range M (SD) Range M (SD) Range
age 40.06 
(13.32)
18-61 38.07 
(13.18)
18-61 50.00 
(9.26)
27-61 40.14 
(13.25)
18-61 40.05 
(13.74)
18-61
N % N % N % N % N %
Marital status
Single 26 41.9 23 45.1 3 27.3 11 44.0 15 41.7
Unmarried, living together 4 6.5 4 7.8 0 0.0 1 4.0 3 8.3
Married, living together 21 33.9 14 27.5 7 63.6 7 28.0 13 36.1
Married, but separated 3 4.8 3 5.9 0 0.0 2 8.0 1 2.8
Divorced 7 11.3 6 11.8 1 9.1 3 12.0 4 11.1
Widowed 1 1.6 1 2.0 0 0.0 1 4.0 0 0.0
Current Relationship
Yes 41 66.1 34 65.4 7 70.0 16 59.3 24 70.6
No 21 33.9 18 34.6 3 30.0 11 40.7 10 29.4
Education
No school-leaving qualification 3 4.8 3 5.9 0 0.0 2 8.0 1 2.7
Qualification after 9 years 16 25.8 12 23.5 4 36.4 8 32.0 8 22.2
Qualification after 10 years 22 35.5 19 37.3 3 27.3 9 36.0 13 36.1
Qualification after 13 years (University 
entrance diploma)
20 32.3 16 31.4 4 36.4 6 24.0 14 38.9
Pretreatment*
Outpatient psycho-therapeutic 39 59.1 30 54.5 9 81.8 19 67.9 20 54.1
Outpatient psychiatric 20 30.3 15 27.3 5 45.5 10 35.7 10 27.0
Inpatient treatment 30 45.5 26 47.3 4 36.4 17 60.7 13 35.1
Physicians with other specializations 11 16.7 34 65.4 3 27.3 5 17.9 6 16.2
Varying sample sizes; *multiple references possible.
TaBlE 3 | Experiences of traumatic events (TE).
Total sample (N = 66) Women (N = 55) Men (N = 11) Non-complex 
subgroup (n = 37)
Complex PTSD 
subgroup (n = 28)
Most frequent traumatic 
events (TE)1
-Serious illness (N = 46, 
69.7%)
-Neglect (N = 39, 
70.9%)
-Serious illness 
(N = 8, 72.7%)
-Serious illness 
(N = 28, 75.7%)
-Neglect (N = 22, 78.6%)
-Neglect (N = 43, 
65.2%)
-Serious illness (N = 38, 
69.1%)
-Natural catastrophe 
(N = 7, 63.6%)
-Physical violence by 
family member 
(N = 22, 59.5%)
-Serious illness 
(N = 18, 64.3%)
-Physical violence by 
family member (N = 41, 
62.1%)
-Physical violence by 
family member (N = 34, 
61.8%)
-Physical violence by 
strangers 
(N = 7, 63.6%)
-Neglect (N = 20, 
54.1%)
-Physical violence by 
family member 
(N = 18, 64.3%)
-Physical violence by 
family member 
(N = 7, 63.6%)
Having experienced 
persistent TE2
N = 45 (75.0%) N = 38 (69.1%) N = 7 (63.6%) N = 26 (70.3%) N = 19 (67.9%)
Having experienced 
sexual violence in their 
infancy
N = 41 (62.1%) N = 39 (70.9%) N = 2 (18.2%) N = 19 (51.4%) N = 21 (75.0%)
1as reported in the ETI, 2e.g many years as reported in the SKPTBS.
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TaBlE 4 | Treatment evaluation for the total sample: symptom scores.
Variable T1 T2 Comparison
M (SD) M (SD) t p d
ETI total 39.45 (16.65) 39.58 (17.88) −0.114 0.910 0.014
ETI PTSD 31.91 (12.31) 31.79 (12.91) 0.125 0.901 −0.017
ETI intrusion 9.52 (4.01) 9.85 (4.42) −0.917 0.363 0.120
ETI avoidance 12.35 (5.40) 12.23 (5.57) 0.280 0.780 −0.035
ETI hyperarousal 10.04 (3.96) 9.71 (3.72) 0.933 0.355 −0.114
ETI dissociation 7.54 (5.23) 7.79 (5.64) −0.658 0.513 0.035
SkPTBS 35.18 (33.21) 35.38 (33.72) −0.063 0.950 0.008
BDI-II 30.43 (11.65) 26.21 (13.27) 3.977 <0.001 −0.536
PHQ somatization 13.70 (5.64) 15.28 (6.17) −3.418 0.001 0.457
PHQ pain 6.00 (3.13) 6.67 (3.23) −2.623 0.011 0.333
PHQ other somatization 4.28 (2.87) 5.41 (3.01) −3.752 <0.001 0.485
ETI, Essen Trauma Inventory; ETI total, sum score of all four subscales; ETI PTSD, sum score calculated on the basis of the three subscales that are relevant for the 
cut-off for a PTSD diagnosis; SkPTBS, Screening for complex PTSD; BDI-II, Beck Depression Inventory-Revision; PHQ, Patient Health Questionnaire; PHQ pain, items 
asking about experiencing pain; PHQ other somatization: items asking about other somatoform symptoms; varying sample sizes and degrees of freedom (df).
Bolded texts highlight significant differences and effect sizes.
TaBlE 5 | Treatment evaluation for the total sample: protective factors.
Variable T1 T2 Comparison
M (SD) M (SD) t p d
PTGI total 40.54 (17.49) 45.22 (16.90) −1.993 0.052 0.277
PTGI Relating to Others 15.65 (6.81) 16.92 (6.96) −1.336 0.188 0.194
PTGI New Possibilities 8.80 (5.23) 10.86 (4.73) −2.993 0.004 0.405
PTGI Personal Strength 7.35 (4.54) 9.20 (4.62) −2.919 0.005 0.414
PTGI Spiritual Change 1.96 (2.80) 2.14 (2.86) −0.669 0.507 0.096
PTGI Appreciation of Life 6.75 (3.55) 6.88 (3.50) −0.285 0.777 0.038
F-SozU 33.53 (14.40) 35.22 (13.95) −1.784 0.079 0.216
PTGI, Posttraumatic Growth Inventory; F-SozU, Questionnaire on social support; varying sample sizes and degrees of freedom (df).
Bolded texts highlight significant differences and effect sizes.
TaBlE 6 | Treatment evaluation for the non-complex sub-group (N = 37): symptom scores.
Variables Non-complex trauma-related disorder
T1 T2 Comparison
M (SD) M (SD) t p d
ETI total 33.04 (15.47) 31.52 (17.78) 1.019 0.315 −0.188
ETI PTSD 27.34 (11.64) 26.03 (13.32) 1.142 0.261 −0.208
ETI intrusion 8.42 (3.85) 8.28 (4.76) 0.331 0.743 −0.063
ETI avoidance 9.93 (4.79) 9.35 (5.24) 0.455 −0.184
ETI hyperarousal 8.99 (3.94) 8.40 (4.05) 1.351 0.185 −0.227
ETI dissociation 5.69 (4.95) 5.49 (5.30) 0.700 −0.066
SkPTBS 9.40 (8.32) 19.72 (24.29) 0.022 1.169
BDI-II 25.65 (10.52) 21.77 (12.49) 2.989 0.005 −0.554
PHQ somatization 12.50 (6.09) 13.52 (6.84) −1.629 0.112 0.289
PHQ pain 5.57 (3.46) 6.00 (3.47) −1.341 0.189 0.226
PHQ other somatization 3.63 (3.01) 4.37 (3.18) 0.078 0.314
ETI, Essen Trauma Inventory; ETI total, sum score of all four subscales; ETI PTSD, sum score calculated on the basis of the three subscales that are relevant for the 
cut-off for a PTSD diagnosis; SkPTBS, Screening for complex PTSD; BDI-II, Beck Depression Inventory-Revision; PHQ, Patient Health Questionnaire; PHQ pain, items 
asking about experiencing pain; PHQ other somatization, items asking about other somatoform symptoms; varying sample sizes and degrees of freedom (df), Wilcoxon 
test where no t is defined.
Bolded texts highlight significant differences and effect sizes.
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TaBlE 7 | Treatment evaluation for the non-complex sub-group (N = 37): protective factors.
Variables Non-complex trauma-related disorder
T1 T2 Comparison
M (SD) M (SD) t p d
PTGI total 40.63 (16.37) 45.97 (15.61) −1.857 0.074 0.332
PTGI Relating to Others 15.86 (5.99) 17.69 (6.94) −1.549 0.133 0.313
PTGI New Possibilities 8.07 (4.89) 10.70 (4.50) −3.117 0.004 0.547
PTGI Personal Strength 7.78 (4.79) 10.03 (4.64) −2.501 0.018 0.443
PTGI Spiritual Change 1.74 (2.49) 1.77 (2.63) 0.975 0.018
PTGI Appreciation of Life 7.13 (3.43) 7.06 (3.45) 0.123 0.903 −0.024
F-SozU 38.21 (13.12) 37.50 (13.85) 0.813 −0.107
PTGI, Posttraumatic Growth Inventory; F-SozU, Questionnaire on social support; varying sample sizes and degrees of freedom (df), Wilcoxon test where no t is defined.
Bolded texts highlight significant differences and effect sizes.
TaBlE 8 | Treatment evaluation for the complex PTSD sub-group (N = 28): symptom scores.
Variables Very high risk for Complex PTSD
T1 T2 Comparison
M (SD) M (SD) t p d
ETI total 47.92 (14.71) 50.15 (12.02) 0.361 0.213
ETI PTSD 37.88 (10.88) 39.34 (7.83) 0.572 0.170
ETI intrusion 10.85 (3.89) 11.95 (2.98) 0.066 0.330
ETI avoidance 15.47 (4.65) 16.00 (3.46) 0.694 0.133
ETI hyperarousal 11.56 (3.51) 11.39 (2.51) 0.674 −0.053
ETI dissociation 10.04 (4.64) 10.81 (4.74) 0.199 0.269
SkPTBS 69.24 (20.19) 56.07 (33.62) 0.020 −0.796
BDI-II 37.51 (9.40) 32.49 (12.15) 2.759 0.010 −0.630
PHQ somatization 15.71 (4.32) 18.09 (3.76) 0.002 0.662
PHQ pain 6.65 (2.61) 7.75 (2.57) −2.493 0.020 0.489
PHQ other somatization 5.23 (2.48) 6.95 (2.02) −3.819 0.001 0.690
ETI, Essen Trauma Inventory; ETI total, sum score of all four subscales; ETI PTSD, sum score calculated on the basis of the three subscales that are relevant for the 
cut-off for a PTSD diagnosis SkPTBS, Screening for complex PTSD; BDI-II, Beck Depression Inventory-Revision; PHQ, Patient Health Questionnaire; PHQ pain, items 
asking about experiencing pain; PHQ other somatization, items asking about other somatoform symptoms; varying sample sizes and degrees of freedom (df), Wilcoxon 
test where no t is defined.
Bolded texts highlight significant differences and effect sizes.
TaBlE 9 | Treatment evaluation for the complex PTSD sub-group (N = 28): protective factors.
Variables Very high risk for Complex PTSD
T1 T2 Comparison
M (SD) M (SD) t p d
PTGI total 40.40 (19.50) 44.10 (19.04) −0.909 0.375 0.201
PTGI Relating to Others 15.35 (8.00) 15.80 (7.01) −0.284 0.780 0.060
PTGI New Possibilities 9.90 (5.65) 11.10 (5.16) −1.031 0.316 0.221
PTGI Personal Strength 6.70 (4.14) 7.90 (4.39) −1.494 0.152 0.345
PTGI Spiritual Change 2.30 (3.26) 2.70 (3.16) 0.406 0.183
PTGI Appreciation of Life 6.15 (3.75) 6.60 (3.63) −0.482 0.635 0.106
F-SozU 27.15 (14.02) 32.00 (13.90) −3.243 0.003 0.610
PTGI, Posttraumatic Growth Inventory; F-SozU, Questionnaire on social support; varying sample sizes and degrees of freedom (df), Wilcoxon test where no t is defined.
Bolded texts highlight significant differences and effect sizes.
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somatization indices showed a significant increase in somatoform 
symptoms (see Table 8).
DiSCUSSiON
Main Results
The major outcome of this survey is that our multimodal, 
group-based therapy program for patients with trauma-related 
disorders is associated with reductions of depressive symptoms 
and increases in PTG. Contrary to our expectations, somatoform 
symptoms increased across time. After dividing the sample into 
patients with and without complex PTSD, important differences 
in therapy outcome were observed: For patients with non-
complex trauma-related disorders, we found a reduction of 
depressive symptoms and an increase in PTG. Somatoform 
symptoms increased in a trend. For patients with cPTSD, we 
found a reduction of depressive symptoms as well as of cPTSD 
symptoms. Perceived social support was significantly increased 
in this group. Somatoform symptoms increased over time.
Positive Changes after Therapy
The observed reduction of depressive symptoms (and cPTSD 
symptoms for those patients with cPTSD) and increase in 
protective factors like PTG and perceived social support align 
with other studies describing positive treatment effects after 
different group-based therapy programs (14, 17, 18). Similar to 
our study, Lampe and colleagues (15) reported a reduction of 
depressive symptoms; PTSD scores did not differ significantly 
from those in the wait list group after their 6 week therapy 
program. Significant group differences in PTSD and somatoform 
symptoms were only found in a follow-up study after 2 years (16).
When interpreting our results, one can see that body-related 
factors such as somatoform symptoms were not reduced, whereas 
factors referring to relationships and interpersonal skills (e.g., 
perceived social support, cPTSD symptoms, New Possibilities 
and Personal Strength) were strengthened after the group-based 
therapy program: those factors that were addressed directly by 
the therapy interventions showed a significant positive effect. The 
aforementioned changes after therapy strengthen patients' level of 
functioning, self-efficacy, belief in their own abilities, courage to face 
life and form a more positive perspective to the future (as indicated 
by the items of BDI-II, SkPTBS and PTGI, e.g. hopelessness, 
feelings of being shattered, perception of new possibilities, feelings 
of personal strength). These changes can be assumed to increase 
patients' quality of life. The achieved improvements prepare patients 
to face their PTSD symptoms in everyday life. The reduction 
of depressive symptoms may be related to the increase in PTG: 
hopelessness and lack of perspective are replaced by perceptions 
of new possibilities, low self-esteem and feelings of weakness are 
replaced by personal strength. As Shalev (56) stated, the reduction 
of depressive symptoms is central to patients' well-being, and also 
a partial therapy outcome should be seen as a breakthrough for 
chronically traumatized patients. The author argued that reducing 
PTSD symptoms should not be used as main criterion for the 
success of an intervention and that the addressing of dysfunctional 
affect and social competence is important. These are two of the 
main factors of our treatment program.
Changes in PTSD and cPTSD
To explain the finding that the manifestation of posttraumatic 
symptoms measured by ETI did not show significant improvements 
in the sample, it is also important to keep in mind that our study 
population consists of severely traumatized patients: 75.0% of the 
participants reported having experienced the TE for a long period, 
59.1% reported having experienced sexual violence in their infancy. 
Sloan et al. (10) found in their meta-analysis that studies with a high 
percentage of patients with a history of child sexual abuse show 
smaller effect sizes than studies with participants reporting other 
traumatization. This effect is strengthened by a recent meta-analysis 
conducted by Karatzias et al. (30). The authors found childhood 
onset trauma to be associated with poorer outcome. Most of our 
participants reported having experienced more than one TE. 
Additionally, although contact to the offender was an exclusion 
criterion, many patients still had contact to people connected with 
the TE because traumatization often took place within the family. 
Hence, although patients had no contact to the offender, they still 
met people who knew about the traumatic events, which may be a 
trigger for patients. It can be concluded that these patients remain 
under the influence of the family atmosphere in which they were 
humiliated. However, increased social support was associated with 
decreased symptom load. We conclude that patients who could 
mobilize support could benefit from this and stabilize mentally.
These factors may have influenced therapy and treatment 
success negatively. Therefore, the achieved stabilization of our 
patients reflects an important improvement of their well-being 
and a basis for following outpatient treatment. As Stalker et al. 
(57) stated, a short term therapy program may not be sufficient 
to achieve clinically significant change because of the potential 
chronicity of PTSD, so that rather a partial than a full success 
could be reached [also see (32)]. Nonetheless, a short term 
program can encourage patients to join in additional forms of 
psychotherapy (58). An interval treatment, as also described by 
Sachsse et al. (17), is optional for patients treated in the previously 
described group and is adopted by quite a few.
The finding that cPTSD symptoms were significantly reduced 
at the end of therapy for cPTSD patients reflects the difference 
between classic and complex PTSD symptoms: whereas classic 
PTSD symptoms were not significantly changed, complex PTSD 
symptoms, which include difficulties in interactions with other 
people (see introduction), were reduced. We assume that in our 
group therapy program, patients were able to increase their social 
competencies and create positive experiences when interacting 
with other people. However, the ETI only measures classic PTSD 
symptoms, whose treatment possibly needs a higher amount 
of confrontational methods (trauma exposition, EMDR) as 
used in this therapy program, which could explain the lack of 
improvement on the ETI scores.
It must be considered that our concept is aimed at stabilization 
first and confrontational methods are secondary. In Cloitre and 
colleagues' (59) STAIR program, PTSD symptoms were only 
reduced after the confrontation phase, not after stabilization and 
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skills training. In contrast, several groups (8, 60, 61) reported no 
differences between confronting and stabilizing therapy programs. 
In the current model, therapists decide individually whether 
confrontation may be beneficiary and if it is to be conducted. 
In a current debate about the significance of stabilization in 
the treatment of trauma-related disorders, de Jongh et al. (62) 
presented a critical view on this concept. The authors reviewed 
the existing literature and argued that the research on stabilization 
is based on methodologically limited studies and that there is 
no clear evidence for a stabilization phase prior to the use of 
confrontational methods. Concerning this debate, one has to keep 
in mind that the term “stabilization” is not clearly defined: It is 
likely that stabilization describes different methods, procedures 
and therapy goals in different articles (63). In our treatment, 
stabilization included psychoeducation about the disorder, stress 
management and distancing methods. We further employed 
problem- and solution-oriented coping techniques and cognitive 
restructuring of trauma-related thoughts. Furthermore, symptoms 
of avoidance were discussed and symptoms that lower psychosocial 
functioning (e.g., interactional problems) were treated. Hence, 
“stabilization” not only included training in affect regulation and 
self-calming abilities but also focused on trauma-related contents 
and clearing of associations between traumatic experiences and 
present symptomatology or difficulties in everyday life. The 
present-centered therapy approach introduced by Schnurr et al. 
(60) includes similar contents and was shown to be an efficacious 
and safe treatment for trauma-related disorders (64, 65). Skipping 
the presented aspects and starting directly with confrontational 
methods, e.g. exposition, would decrease patients' well-being and 
increase the risk of additional problems (e.g., losing their job or 
deterioration of their relationship) (66). However, other studies also 
demonstrated that exposure treatment can be delivered to patients 
following multiple trauma and multiple treatment attempts (67).
increase of Somatoform Symptoms
The increase of somatoform symptoms may represent adverse 
effects of the intensive occupation with traumatic experiences. 
As Johnson and colleagues (68) reported, traumatic experiences 
may have been brought up, attention may have been directed 
to symptoms and patients may have been sensitized to observe 
potential symptoms more intensely. Additionally, the increase 
in somatoform symptoms in the course of therapy may be due 
to the fact that the patients came into the therapy with extensive 
neglect of medical problems and physical care, e.g. contacting 
doctors was worked out with some of them as a therapy goal. This 
circumstance may have caused the patients' attention on the body. 
Nevertheless, patients reported that talking about symptoms, 
etiology and relating factors was important to understand their 
disorder and symptoms. Many authors (30, 63, 69) highlight that 
it is necessary to also report adverse effects or deterioration after 
therapy. Another reason for the increase in somatoform symptoms 
and stagnation in PTSD symptoms is that our patients reported a 
very high extent of somatoform symptoms (M = 13.70) compared 
to the findings from Gräfe and colleagues (70; M = 6.4, 9.8, 9.7 for 
patients without psychiatric disorder, with psychiatric comorbidity 
and those in psychosomatic treatment, respectively). In addition, 
T2 assessment was conducted in the last week of treatment (week 
8), in which patients had to disengage from the group and the 
therapists. As many patients told the therapeutic team, they felt 
themselves accepted often for the first time. Also, patients have to 
focus again on their everyday life with all requests and problems. 
Hence, it can be assumed that the end of this intensive therapy is 
a critical phase in patients' therapeutic process. These difficulties 
might have compromised the symptom ratings.
The aforementioned sensitization of patients to observe potential 
symptoms more intensely (68) may also explain the increase in 
cPTSD symptoms for patients with non-complex trauma-related 
disorders. It is likely that patients learned about their disorder 
through psychoeducation and clearing of associations between 
traumatic experiences and present symptomatology, so that they 
developed a higher understanding of their symptoms and were able 
to report them more explicitly at T2. Additionally, although the 
SkPTBS was examined to be a highly valid and usable instrument 
(44), it was only used in very few clinical studies until now. The 
increase of the scores for patients without cPTSD could be 
associated with further variables, which have not been examined 
in the present study. Future studies should explore the mechanisms 
underlying this finding.
The Concept of cPTSD
As presented in the introduction, there is an ongoing debate 
about the concept of cPTSD (25). The results of this study 
highlight the differences between classic and complex PTSD. 
cPTSD can be seen as PTSD plus additional characteristics, 
which leads to a differential influence on therapeutic processes. 
The present results demonstrate that it is important to screen for 
and to differentiate between the two diagnoses as patients react 
differently in therapy. Without considering the concept of cPTSD, 
important differences in therapy outcome could be overlooked.
limitations and Strengths
Our study has some limitations that need to be considered. Due 
to organizational reasons it was not possible to include a control 
group in our study; hence, clear implications of causality cannot 
be drawn. Furthermore, symptom ratings are not based on 
structured interviews but on self-rating instruments.
Despite these limitations, our study has various strengths: 
It is one of the first to examine a multimodal, group-based day 
clinic treatment for patients with trauma-related disorders. Most 
previous studies examined special programs and focused on 
assessing symptomatology without paying attention to resilience 
factors. As such, our study expands previous research and has 
implications for therapy. The study provides high external validity 
and generalizability, reflects clinical practice and demonstrates 
how treatments work in field (17, 71). Also, the sub-group analysis 
concerning a division of patients in those with and without complex 
PTSD, respectively, is a strength of our study: In the current 
literature there is no consensus whether therapy programs for 
PTSD also function for patients with complex PTSD. As such, the 
results of our study further develop psychotherapy for patients with 
cPTSD and provide advice to adapt therapeutic work. Our study 
is also one of the first to examine a day clinic treatment program, 
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which has various advantages for patients such as being connected 
to their everyday life or being able to spend evenings and nights at 
home, which may strengthen feelings of safety. Furthermore, day 
clinic programs are more cost effective than inpatient treatments. 
The study also has implications for our therapy setting and 
program planning. We think about adding a specialized trauma 
confrontation group, which our patients can enter after completing 
the afore examined stabilizing group treatment in form of an 
interval treatment. Patients need to be thoroughly screened for 
willingness and readiness to undertake exposure treatment.
Further research should include a control group, a higher number 
of participants and structured interviews to secure diagnoses.
CONClUSiON
The current study shows that multimodal, group-based day clinic 
treatment programs for patients with trauma-related disorders are 
associated with reductions in depressive and cPTSD symptoms 
as well as with increases in protective factors like perceived social 
support and PTG. It also demonstrates that cPTSD patients 
benefit from such programs and can be successfully treated. 
On the other hand, our study has identified that the treatment 
of specific symptoms such as intrusions were undervalued 
in our concept. We plan to optimize our psychotherapeutic 
concept according to these results of the study. One optimization 
possibility would be to consider exposure-based interventions 
earlier in the therapeutic process.
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